ST CHARLES MEDICAL CENTER
- Type
- Teaching hospital
- Where
- Bend, OR
- Medicare CCN
- 380047
- Received
- $295,350 in 48 records, 2020 ($26,348 general, $269,001 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 21 | $26,348 |
| 2020 | Research payment | 27 | $269,001 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 1 | $183,220 | 2020 |
| AstraZeneca Pharmaceuticals LP | 4 | $61,588 | 2020 |
| Stryker Corporation | 20 | $26,133 | 2020 |
| E.R. Squibb & Sons, L.L.C. | 1 | $11,627 | 2020 |
| Abbott Laboratories | 5 | $7,702 | 2020 |
| F. Hoffmann-La Roche AG | 13 | $3,509 | 2020 |
| Boston Scientific Corporation | 2 | $1,257 | 2020 |
| GE HEALTHCARE | 1 | $214 | 2020 |
| Merck Sharp & Dohme LLC | 1 | $96 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 27 | $269,001 |
| Gift | 4 | $23,370 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 16 | $2,763 |
| Charitable Contribution | 1 | $214 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Stryker Corporation | $8,417 | Gift | In-kind items and services | INTOUCH W/ZOOM Device, PATIENT CARE - PC | 2020 | |
| 2020-12-31 | Stryker Corporation | $8,417 | Gift | In-kind items and services | INTOUCH W/ZOOM Device, PATIENT CARE - PC | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $4,436 | Research payment | In-kind items and services | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $3,815 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2020 |
| 2020-12-31 | Stryker Corporation | $3,267 | Gift | In-kind items and services | ISOLIBRIUM Device, PATIENT CARE - PC | 2020 | |
| 2020-12-31 | Stryker Corporation | $3,267 | Gift | In-kind items and services | ISOLIBRIUM Device, PATIENT CARE - PC | 2020 | |
| 2020-12-17 | F. Hoffmann-La Roche AG | $225 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L NSCLC DX ALL COMER NON SQUAMOUS | 2020 |
| 2020-12-10 | Novartis Pharmaceuticals Corporation | $183,220 | Research payment | Cash or cash equivalent | MAS825F Drug | A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, PARTICIPANT AND INVESTIGATOR BLINDED, MULTI-CENTER STUDY TO ASSESS EFFICACY A | 2020 |
| 2020-11-12 | Merck Sharp & Dohme LLC | $96 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-11 | Abbott Laboratories | $275 | Research payment | Cash or cash equivalent | Dragonfly OPTIS optical coherence tomography (OCT) Device, Vascular | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2020 |
| 2020-10-13 | Stryker Corporation | $640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-13 | Stryker Corporation | $93 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-13 | Stryker Corporation | $59 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-13 | Stryker Corporation | $24 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-08-20 | F. Hoffmann-La Roche AG | $454 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L NSCLC DX ALL COMER NON SQUAMOUS | 2020 |
| 2020-08-18 | F. Hoffmann-La Roche AG | $250 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L NSCLC DX ALL COMER NON SQUAMOUS | 2020 |
| 2020-08-18 | F. Hoffmann-La Roche AG | $80 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L NSCLC DX ALL COMER NON SQUAMOUS | 2020 |
| 2020-08-12 | Abbott Laboratories | $825 | Research payment | Cash or cash equivalent | Dragonfly OPTIS optical coherence tomography (OCT) Device, Cardiac Arrhythmias and Heart Failure | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2020 |
| 2020-07-06 | Stryker Corporation | $272 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-06 | Stryker Corporation | $38 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-06 | Stryker Corporation | $30 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-06 | Stryker Corporation | $20 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $722 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $66 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $52 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $42 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-03-31 | AstraZeneca Pharmaceuticals LP | $25,388 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2020 |
| 2020-03-26 | F. Hoffmann-La Roche AG | $500 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L NSCLC DX ALL COMER NON SQUAMOUS | 2020 |
| 2020-03-24 | F. Hoffmann-La Roche AG | $250 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L NSCLC DX ALL COMER NON SQUAMOUS | 2020 |
| 2020-03-16 | Boston Scientific Corporation | $200 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | RANGER II SFA | 2020 |
| 2020-03-03 | F. Hoffmann-La Roche AG | $250 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L NSCLC DX ALL COMER NON SQUAMOUS | 2020 |
| 2020-02-21 | E.R. Squibb & Sons, L.L.C. | $11,627 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Lung cancer molecular profiling and clinical outcomes in US oncology community practices | 2020 |
| 2020-02-18 | Boston Scientific Corporation | $1,057 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | RANGER II SFA | 2020 |
| 2020-02-12 | Abbott Laboratories | $4,202 | Research payment | Cash or cash equivalent | Dragonfly OPTIS optical coherence tomography (OCT) Device, Cardiac Arrhythmias and Heart Failure | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2020 |
| 2020-02-11 | GE HEALTHCARE | $214 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-02-06 | Abbott Laboratories | $2,100 | Research payment | Cash or cash equivalent | Dragonfly OPTIS optical coherence tomography (OCT) Device, Cardiac Arrhythmias and Heart Failure | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2020 |
| 2020-02-06 | Abbott Laboratories | $300 | Research payment | Cash or cash equivalent | Dragonfly OPTIS optical coherence tomography (OCT) Device, Cardiac Arrhythmias and Heart Failure | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2020 |
| 2020-01-21 | F. Hoffmann-La Roche AG | $250 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L NSCLC DX ALL COMER NON SQUAMOUS | 2020 |
| 2020-01-21 | F. Hoffmann-La Roche AG | $250 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L NSCLC DX ALL COMER NON SQUAMOUS | 2020 |
| 2020-01-21 | F. Hoffmann-La Roche AG | $250 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L NSCLC DX ALL COMER NON SQUAMOUS | 2020 |
| 2020-01-21 | F. Hoffmann-La Roche AG | $250 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L NSCLC DX ALL COMER NON SQUAMOUS | 2020 |
| 2020-01-21 | F. Hoffmann-La Roche AG | $250 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L NSCLC DX ALL COMER NON SQUAMOUS | 2020 |
| 2020-01-21 | F. Hoffmann-La Roche AG | $250 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L NSCLC DX ALL COMER NON SQUAMOUS | 2020 |
| 2020-01-14 | Stryker Corporation | $542 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-01-14 | Stryker Corporation | $95 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-01-14 | Stryker Corporation | $38 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-01-14 | Stryker Corporation | $23 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-01-02 | AstraZeneca Pharmaceuticals LP | $27,948 | Research payment | Cash or cash equivalent | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Bend, OR, county Deschutes County, OR, state Oregon; placed by its city name.
| Measure | Place (city or town) Bend, OR | County Deschutes County, OR | State Oregon |
|---|---|---|---|
| Population B01003 | 103,390 | 206,334 | 4,254,293 |
| Population, 2020 census P1 | 99,178 | 198,253 | 4,237,256 |
| Median age B01002 | 40.9 | 42.9 | 40.4 |
| Under 18 B01001 | 19.3% | 18.9% | 19.9% |
| 65 and over B01001 | 18.1% | 21.3% | 19.1% |
| Households B11001 | 44,436 | 84,933 | 1,718,422 |
| Foreign born B05002 | 4.8% | 4.9% | 9.8% |
| Median household income B19013 | $96,394 | $92,758 | $83,011 |
| Median family income B19113 | $116,302 | $110,845 | $102,281 |
| Per capita income B19301 | $58,652 | $53,083 | $45,612 |
| Poverty rate B17001 | 8.8% | 8.8% | 11.9% |
| Unemployment rate B23025 | 3.7% | 4.4% | 5.4% |
| Civilian labor force B23025 | 58,482 | 109,166 | 2,183,462 |
| Mean commute (minutes) B08013 | 16.3 | 19.6 | 23.0 |
| Bachelor's degree or higher B15003 | 52.9% | 45.0% | 36.8% |
| Housing units B25001 | 47,957 | 99,297 | 1,857,992 |
| Owner-occupied B25003 | 61.7% | 70.0% | 63.3% |
| Renters B25003 | 38.3% | 30.0% | 36.7% |
| Median home value B25077 | $718,400 | $650,900 | $477,600 |
| Median gross rent B25064 | $1,883 | $1,787 | $1,525 |
| White, not Hispanic B03002 | 82.6% | 83.5% | 71.4% |
| Black B03002 | 0.3% | 0.3% | 1.8% |
| Hispanic or Latino B03002 | 9.2% | 9.2% | 14.7% |
| Asian B03002 | 1.1% | 1.0% | 4.4% |
| American Indian and Alaska Native B03002 | 0.3% | 0.4% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Bend, OR.
Comments